Chemogenetic attenuation of cortical seizures in nonhuman primates.
Naohisa MiyakawaYuji NagaiYukiko HoriKoki MimuraAsumi OriharaKei OyamaTakeshi MatsuoKen-Ichi InoueTakafumi SuzukiToshiyuki HirabayashiTetsuya SuharaMasahiko TakadaMakoto HiguchiKeisuke KawasakiTakafumi MinamimotoPublished in: Nature communications (2023)
Epilepsy is a disorder in which abnormal neuronal hyperexcitation causes several types of seizures. Because pharmacological and surgical treatments occasionally interfere with normal brain function, a more focused and on-demand approach is desirable. Here we examined the efficacy of a chemogenetic tool-designer receptors exclusively activated by designer drugs (DREADDs)-for treating focal seizure in a nonhuman primate model. Acute infusion of the GABA A receptor antagonist bicuculline into the forelimb region of unilateral primary motor cortex caused paroxysmal discharges with twitching and stiffening of the contralateral arm, followed by recurrent cortical discharges with hemi- and whole-body clonic seizures in two male macaque monkeys. Expression of an inhibitory DREADD (hM4Di) throughout the seizure focus, and subsequent on-demand administration of a DREADD-selective agonist, rapidly suppressed the wide-spread seizures. These results demonstrate the efficacy of DREADDs for attenuating cortical seizure in a nonhuman primate model.